末梢性眩暈症に対するイソプロテレノ-ル徐放剤(KIP)の使用経験
スポンサーリンク
概要
- 論文の詳細を見る
In several controlled trials, sustained release preparation of isoproterenol, a beta-adrenergic stimulant proved to be safe and effective for vertigenous patients, especially in cases of peripheral disorders. We determined the effectiveness of this drug in 30 patients with peripheral vertigo, in an open trial. Concerning vestibular symptoms, i. e. vertigo and dizziness, 80% of the patients experienced relief while on 6 tab/day (45mg/day) for 2 weeks.The most significant result as determined by the caloric tests was a restoration of the disequilibrium in labyrinthine excitability on the level of 1% of significance. Three patients complained of slight tachycardia, headache and drowsiness (11%).
- 耳鼻咽喉科臨床学会の論文
著者
関連論文
- The return tilt test and labyrinthine disorders
- 同胞にみられた先天性眼振症例
- 興味ある異常眼運動を呈した脊髄小脳変性症の1例--その神経耳科学的検討
- 耳下腺部に原発した小児横紋筋肉腫の1例
- 嗅覚性発作を示したSyphilitic Hydropsの1症例における術後経過について
- 末梢性眩暈症の平衡機能障害に対するメチコバ-ル(Methyl-B12)の内服投与治験--特に他覚所見の選択に関する考察
- 舌口腔咽喉頭領域の炎症に対するアズノ-ル・ミニトロ-チの試用経験
- 聴神経腫瘍を疑わせたneurovascular compressionの1症例
- Anatomical measurements of the endolymphatic sac during the epidural shunt operation in patients with Meniere's disease.
- 末梢性眩暈症に対するイソプロテレノ-ル徐放剤(KIP)の使用経験
- Elicitation of nystagmus by a new thermal test to the hand in the patients with atypical Meniere's disease.